# Global Health (MEDANTA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/medanta

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,390
- Change: +0.02%
- As of: 2026-11-06
- 1D return: +0.02%
- 5D return: +9.42%
- 1M return: +8.89%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

MEDANTA closed at ₹1390.0 on 2026-11-06, marking a flat day (+0.0%) after a significant +5.7% surge on 2026-11-04 accompanied by extreme volume (11.16x ratio). The daily trend is established and bullish, with the price trading above all key moving averages and the Supertrend. However, this short-term strength contrasts with a bearish monthly Supertrend and weak monthly momentum (ADX 10.7), suggesting the recent rally may be a counter-trend move within a longer-term consolidation or downtrend. The stock is positioned in the upper-middle of its 252-day range (+73.8%) and near the top of its 20-day range (+78.5%). Immediate resistance lies at ₹1407.3 (pivot, +1.24%), while support is found at ₹1365.3 (-1.78%). Anomalies indicate high participation without clear directional follow-through on the weekly timeframe, signaling potential indecision.

- Daily trend is bullish (price above all MAs/Supertrend; ADX 25.62) but conflicts with monthly bearish structure (Supertrend below price; ADX 10.7).
- Recent volatility: +5.7% gain on 2026-11-04 with 11.16x volume; current day showed zero return despite high weekly participation anomaly.
- Key levels to monitor: Resistance at ₹1407.3 (+1.24%) and ₹1421.08 (+2.24%); Support at ₹1365.3 (-1.78%) and ₹1363.1 (-1.94%).
- Risk metrics: Annualized volatility is +31.8%; current drawdown is -7.9% from available highs.
- Confirmation condition: A daily close above ₹1407.3 would strengthen the short-term breakout; failure to hold above ₹1365.3 could invalidate the immediate bullish bias.

- Harami
- Bullish Engulfing Reversal
- Bearish Engulfing Reversal
- Outside Bar

### Official Filings

Global Health Limited (MEDANTA) submitted its unaudited financial results for the second quarter and half-year ended September 30, 2026, to the NSE and BSE on November 3, 2026. The Board approved these results, which were subject to a limited review by statutory auditors Walker Chandiok & Co LLP. For Q2 FY2027, revenue from operations rose 33.6% year-over-year to ₹14,690 million, while operating EBITDA increased 60.2% to ₹3,701 million with margins expanding to 25.2%. Profit after PAT grew 38.3% to ₹2,191 million. Operational metrics showed inpatient volumes up 29.5% and outpatient footfalls up 37.9%, supporting total census bed capacity of 3,115 at 67% occupancy.

On the capital allocation front, the Board approved a project budget of ₹997 Crores for constructing a 500-bedded hospital in Ghaziabad, Uttar Pradesh. This includes land costs of ₹165.82 Crores for a 10,560.36 sq. meter parcel allotted via e-auction. The company also disclosed a broader planned capital expenditure of approximately ₹62,390 million over the next 4-5 years to support expansion in Mumbai, Delhi, Guwahati, Varanasi, and Ghaziabad. Funding is expected through internal accruals and debt.

- Q2 FY2027 Financial Performance: Revenue grew 33.6% YoY to ₹14,690 million; Operating EBITDA rose 60.2% to ₹3,701 million (margin 25.2%); PAT increased 38.3% to ₹2,191 million.
- Ghaziabad Hospital Project: Board approved a ₹997 Crore budget for a 500-bed facility, including ₹165.82 Crores for land acquisition on a 10,560.36 sq. meter plot allotted by UPAVP.
- Long-term Capex Plan: Disclosed estimated capital expenditure of ₹62,390 million over 4-5 years for expansion across multiple cities, funded via internal accruals and debt.
- Operational Growth: Inpatient volumes increased 29.5% and outpatient footfalls rose 37.9%; total census bed capacity reached 3,115 with 67% occupancy.

- [Global Health Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026123237_GHLNEWSPAPERADVERNOVEMBER042026Signed.pdf)
- [Global Health Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026165710_GHLAUDIORECORDINGINTIMATIONNOVEMBER042026Signed.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20261104_170655019.xml)
- [Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026160317_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [Global Health Limited has informed the Exchange about Capacity addition |SUBJECT: Capacity addition](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026162207_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Capacity addition (Sub-para 3-Para B) |SUBJECT: Capacity addition (Sub-para 3-Para B)](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_20051_WebXMLFile_20261103_163414801.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751854_03112026044825_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751853_03112026044819_WEB.xml)
- [Global Health Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press release for the Results of Second Quarter & Half Year ended September 30, 2026." |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172432_GHLPRESSRELEASENOVEMBER032026SIGNED.pdf)
- [Global Health Limited has informed the Exchange about Investor Presentation |SUBJECT: Investor Presentation](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172712_GHLINVESTORPRESENTATIONNOV032026SIGNED.pdf)

### Fundamentals

MEDANTA Global Health demonstrates a robust operational trajectory in Q2 FY2026-27, with revenue from operations surging 34% year-on-year to ₹1,469 crore. This growth is accompanied by significant earnings expansion: net profit rose to ₹219 crore and basic EPS increased to ₹8.21 per share, up from ₹5.91 in the prior quarter. Operating profit jumped to ₹370 crore, reflecting strong top-line momentum.

Financial health remains solid despite aggressive expansion. The company’s cash conversion cycle improved to -26 days as of Mar 2026, indicating efficient working capital management. However, balance-sheet leverage has risen; borrowings increased to ₹1,353 crore as of Sep 2026, and finance costs for the quarter reached ₹28.1 crore. Cash reserves declined sharply from ₹759 crore to ₹296 crore over the year, while fixed assets grew to ₹3,957 crore, signaling heavy investment in capacity. Return on Capital Employed (ROCE) moderated to 17% from 20% in Mar 2025, suggesting the new assets are still ramping up efficiency.

Ownership patterns show increasing institutional interest, with Domestic Institutional Investors (DIIs) raising their stake to 17.01%, while Foreign Institutional Investors (FIIs) reduced theirs to 9.92%. Promoter holding remained stable at 33.0%.

- Q2 FY2026-27 Revenue surged 34% YoY to ₹1,469 crore, driving Net Profit to ₹219 crore and EPS to ₹8.21.
- Borrowings rose to ₹1,353 crore and finance costs hit ₹28.1 crore in Q2, funding asset growth that saw Fixed Assets reach ₹3,957 crore.
- Cash reserves dropped significantly to ₹296 crore as of Sep 2026, down from ₹759 crore a year prior, while ROCE normalized to 17%.
- DIIs increased their stake to 17.01% in Sep 2026, contrasting with FII reduction to 9.92%; promoter holding held steady at 33.0%.

### Bear Case

MEDANTA (Global Health) faces near-term technical headwinds as the stock trades in a bearish monthly and weekly trend, with the Supertrend indicator signaling downside pressure on both timeframes. The share price has retreated from recent highs, currently sitting at ₹1390.0, below the immediate pivot resistance of ₹1407.3 and the recent high of ₹1421.08. This consolidation follows a +6% post-earnings surge, suggesting the market is digesting prior gains rather than extending them immediately. Volatility remains elevated, with an annualized volatility of +31.8% and an Average True Range (ATR) of 3.66%, indicating significant price fluctuation risk. Additionally, the stock is experiencing a current drawdown of -7.9% against its peak, while the 50-day moving average slope has turned negative (-4.78), contrasting with the positive momentum seen over the past month (+6.9%).

- Bearish Trend Signals: Monthly and weekly Supertrend indicators are bearish; the 50-day SMA slope is negative (-4.78), indicating short-to-medium term weakening momentum.
- Resistance Constraints: Price is capped near ₹1407.3 (pivot) and ₹1421.08 (high); failure to break these levels may sustain downward pressure toward support at ₹1365.3.
- Elevated Volatility: Annualized volatility stands at +31.8% with an ATR of 3.66%, reflecting heightened price instability and execution risk for traders.
- Current Drawdown: The stock is down -7.9% from its recent peak, following a strong +17.6% return over the last six months, suggesting a potential mean-reversion phase.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Global Health Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026123237_GHLNEWSPAPERADVERNOVEMBER042026Signed.pdf)
- [Global Health Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026165710_GHLAUDIORECORDINGINTIMATIONNOVEMBER042026Signed.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20261104_170655019.xml)
- [Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026160317_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [Global Health Limited has informed the Exchange about Capacity addition |SUBJECT: Capacity addition](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026162207_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Capacity addition (Sub-para 3-Para B) |SUBJECT: Capacity addition (Sub-para 3-Para B)](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_20051_WebXMLFile_20261103_163414801.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751854_03112026044825_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751853_03112026044819_WEB.xml)
- [Global Health Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press release for the Results of Second Quarter & Half Year ended September 30, 2026." |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172432_GHLPRESSRELEASENOVEMBER032026SIGNED.pdf)

### FAQs

**What major expansion project did Global Health approve in its recent Board meeting?**

On November 3, 2026, the Board approved a project budget of ₹997 Crores (including land cost) for constructing a 500-bedded hospital in Ghaziabad, Uttar Pradesh. The land parcel measures 10,560.36 sq. meters and was allotted by UPAVP, with the land purchase costing ₹165.82 Crores. The project is expected to be added over 3-4 years.

**How is the Ghaziabad hospital project funded?**

The company stated that the new facility will be funded via internal accruals and debt. This follows the approval of unaudited financial results for the half-year ended September 30, 2026, which received unmodified limited review opinions from statutory auditors Walker Chandiok & Co LLP.

**What was the market reaction to the Q2 earnings release?**

Following the release of second-quarter earnings results on November 4, 2026, Global Health shares rose 6%. The stock closed at ₹1,390.0 on November 6, 2026, with a market capitalization of approximately ₹37,365 Crores. An earnings conference call was held later that day to discuss the results.

**What are the key technical support and resistance levels for MEDANTA?**

As of November 6, 2026, immediate resistance sits at ₹1,407.3 (pivot) and ₹1,421.08 (high). Support levels are observed at ₹1,365.3 and ₹1,363.1. The daily trend shows a bullish super-trend direction, while the monthly trend remains bearish. The stock has gained +17.3% over the last 10 days.

- [Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- [Global Health Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026123237_GHLNEWSPAPERADVERNOVEMBER042026Signed.pdf)
- [Global Health Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026165710_GHLAUDIORECORDINGINTIMATIONNOVEMBER042026Signed.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20261104_170655019.xml)
- [Global Health Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026160317_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [Global Health Limited has informed the Exchange about Capacity addition |SUBJECT: Capacity addition](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026162207_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- [GLOBAL HEALTH LIMITED has informed the Exchange about Capacity addition (Sub-para 3-Para B) |SUBJECT: Capacity addition (Sub-para 3-Para B)](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_20051_WebXMLFile_20261103_163414801.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751854_03112026044825_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751853_03112026044819_WEB.xml)
- [Global Health Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Press release for the Results of Second Quarter & Half Year ended September 30, 2026." |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172432_GHLPRESSRELEASENOVEMBER032026SIGNED.pdf)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,407.3
- Risk regime: Price Risk Requires Attention

### Support levels
- 1365.3
- 1153.375
- 1133.45

### Resistance levels
- 1421.075
- 1456.2625
- 1489.45

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.02% |
| return_10 | +17.30% |
| return_1m | +6.86% |
| return_1y | +8.53% |
| return_20 | +8.89% |
| return_3m | -3.76% |
| return_5 | +9.42% |
| return_6m | +17.64% |
| return_since_start | +26.28% |
| return_ytd | +16.62% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -32.66% |
| annualized_volatility | +31.80% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Global Health Limited FY2026-27 Q2: Revenue up 12.7%, profit up 39.4% QoQ

Global Health Limited (Medanta) reported consolidated revenue from operations of ₹1,469 crore for the quarter ended 30 September 2026, up 12.7% from Q1 FY2026-27 and 33.6% year on year. Profit for the period rose 39.4% quarter on quarter to ₹219 crore, with basic EPS at ₹8.21.

## Revenue and expenses

Revenue from operations increased by ₹165 crore from Q1 FY2026-27. Expenses rose 7.6% to ₹1,198 crore, while profit before tax increased 38.2% to ₹295 crore. Revenue has risen in each of the last four quarters, from ₹1,121 crore in Q3 FY2025-26 to ₹1,469 crore in Q2 FY2026-27.

## Profit, tax and earnings per share

Profit before tax was ₹295 crore, compared with ₹213 crore in Q1 FY2026-27. Tax expense increased 35.1% to ₹75.7 crore from ₹56.0 crore, and profit for the period rose to ₹219 crore from ₹157 crore. Finance costs increased 5.3% to ₹28.1 crore from ₹26.7 crore.

Basic EPS was ₹8.21, up from ₹5.91 in Q1 FY2026-27. Comprehensive income rose 45.8% to ₹222 crore from ₹152 crore.

## Balance sheet

At 30 September 2026, total assets were ₹6,606 crore, compared with ₹5,905 crore at 31 March 2026. Equity increased to ₹4,343 crore from ₹3,984 crore, while liabilities rose to ₹2,263 crore from ₹1,921 crore.

Non-current borrowings stood at ₹659 crore, down from ₹1,127 crore at 31 March 2026; current borrowings were ₹36 crore. Cash and cash equivalents were ₹296 crore, compared with ₹127 crore at 31 March 2026 and ₹759 crore at 30 September 2025.

Trade receivables increased to ₹522 crore from ₹411 crore at 31 March 2026, and inventories rose to ₹88 crore from ₹79 crore. Property, plant and equipment stood at ₹3,937 crore, up from ₹3,779 crore at 31 March 2026.

## Key Takeaway

Revenue continued to rise and profit grew faster than revenue in Q2, lifting EPS and comprehensive income. The balance sheet expanded from 31 March 2026, while non-current borrowings declined; cash and cash equivalents remained below their level a year earlier.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +33.00%
- FII holding: +9.46%
- DII holding: +16.89%
- Mutual fund holding: +16.03%
- Retail holding: +3.71%
- Promoter pledged: +0.00%

### Major reported shareholders

- Naresh Trehan — +33.00%
- DUNEARN INVESTMENTS (MAURITIUS) PTE LTD — +14.84%
- SUNIL  SACHDEVA — +10.04%
- RJ CORP LIMITED — +6.58%
- INVESCO INDIA ELSS TAX SAVER FUND — +5.30%
- KOTAK CONTRA FUND — +3.53%
- GOVERNMENT PENSION FUND GLOBAL — +3.17%
- UTI-HEALTHCARE FUND — +2.01%
- POLARIS HEALTHCARE INVESTMENTS PTE LTD — +1.86%
- CANARA ROBECO MUTUAL FUND A/C  CANARA ROBECO VALUE — +1.83%

## Official filings

- 2026-11-04 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026123237_GHLNEWSPAPERADVERNOVEMBER042026Signed.pdf)
- 2026-11-04 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_04112026165710_GHLAUDIORECORDINGINTIMATIONNOVEMBER042026Signed.pdf)
- 2026-11-04 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20261104_170655019.xml)
- 2026-11-03 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026160317_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- 2026-11-03 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026162207_GHLOUTCOMEOFBMNOV032026SIGNED.pdf)
- 2026-11-03 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_PARA_B_20051_WebXMLFile_20261103_163414801.xml)
- 2026-11-03 — Financial Results Filing: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751854_03112026044825_WEB.xml)
- 2026-11-03 — Financial Results Filing: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1751853_03112026044819_WEB.xml)
- 2026-11-03 — Press Release: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172432_GHLPRESSRELEASENOVEMBER032026SIGNED.pdf)
- 2026-11-03 — Earnings Presentation: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_03112026172712_GHLINVESTORPRESENTATIONNOV032026SIGNED.pdf)
- 2026-11-02 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_02112026172430_GHLResignationofSMPNOVEMBER022026SIGNED.pdf)
- 2026-11-02 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_02112026172623_GHLResignationofSMPNOVEMBER022026SIGNED.pdf)
- 2026-11-02 — Management Change: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA_ROID_103012_KMP_Doc.zip)
- 2026-11-02 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_20051_WebXMLFile_20261102_173423915.xml)
- 2026-10-31 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_31102026162355_GHLResignationofSMP31OCTOBER2026Signed.pdf)
- 2026-10-31 — Management Change: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA_ROID_102803_KMP_Doc.zip)
- 2026-10-31 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_20051_WebXMLFile_20261031_171756631.xml)
- 2026-10-27 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_27102026170058_GHLANALYSTSMEETOCTOBER272026Signed.pdf)
- 2026-10-27 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_20051_WebXMLFile_20261027_171320785.xml)
- 2026-10-23 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_23102026175245_GHLALLOTMENTOUTCOMEOFNRCOCTOBER2026Signed.pdf)
- 2026-10-23 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_20051_WebXMLFile_20261023_175549505.xml)
- 2026-10-22 — Board Meeting Notice: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/MEDANTA21_22102026170626_GHLBMPRIORINTIMATIONNovember2026Signed.pdf)
- 2026-10-22 — Generic Announcement: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_20051_WebXMLFile_20261022_172758732.xml)
- 2026-10-22 — Board Meeting Notice: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_20051_WebXMLFile_20261022_172758732.xml)
- 2026-10-19 — Shareholding Disclosure: Global Health Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1741502_19102026035252_WEB.xml)

## News and market events

- 2026-11-04 — MONEYCONTROL: **Price Action: Global Health up 6%, Vijaya Diagnostic down 3% post Q2 earnings** — Global Health shares rose 6% while Vijaya Diagnostic fell 3% following the release of their second-quarter earnings results. The price action reflects market reactions to the respective financial performance reported by these listed entities. — [Source](https://www.moneycontrol.com/news/business/markets/price-action-global-health-up-6-vijaya-diagnostic-down-3-post-q2-earnings-14068202.html)
- 2026-10-01 — Economic Times: **Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?** — Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/fortis-apollo-other-hospital-stocks-slump-up-to-10-in-2-days-after-sc-questions-steep-markups-buying-opportunity/articleshow/134608717.cms)
- 2026-10-01 — BUSINESSTODAY: **Fortis, Max, Apollo, Medanta, Manipal: Buy hospital stocks for 22-46% upside, says Jefferies** — Hospital stocks, Hospital stocks news, Fortis Healthcare share price, Max share porice, Apollo Hospitals share rpice, Medanta share price, Manipal Health share price — [Source](https://www.businesstoday.in/markets/stocks/story/fortis-max-apollo-medanta-manipal-buy-hospital-stocks-for-22-46-upside-says-jefferies-558954-2026-10-01)
- 2026-10-01 — Economic Times: **Jefferies picks 6 hospitals as Buy after steep correction offers 'excellent' entry points. Check target price** — Jefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correction driven by regulatory concerns over drug and consumable price caps. The brokerage expects strong fundamentals and strategic price adjustments to help limit long-term EBITDA impact. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/jefferies-picks-6-hospitals-as-buy-after-steep-correction-offers-excellent-entry-points-check-target-price/articleshow/134607485.cms)
- 2026-10-01 — CNBC-TV18: **Hospital stocks sell-off a buying opportunity or a risk? Here is what analysts advice** — The Supreme Court, on Tuesday, September 29, flagged how drugs cost 2,700 to a retailer and are billed at 27,000 to patients in hospitals. The top court questioned where the 10x markup on prices was going. — [Source](https://www.cnbctv18.com/market/hospital-stocks-apollo-max-fortis-aster-share-price-fall-a-buying-chance-or-risk-supreme-court-price-cap-impact-20002607.htm)
- 2026-10-01 — Economic Times: **Hospital stocks slip after SC query on steep cancer drug markups** — In a landmark ruling, the Supreme Court of India highlighted troubling markups on cancer drugs enforced by hospitals, urging a probe into reports of patients being directed to specific pharmacies for their medications. Following this announcement, the BSE Hospitals Index faced a steep 5% drop, leading to notable losses for industry giants like Apollo Hospitals and Fortis Healthcare. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/hospital-stocks-slip-after-sc-query-on-steep-cancer-drug-markups/articleshow/134605708.cms)
- 2026-09-30 — Economic Times: **Hospital stocks fall up to 6%: Apollo, Fortis, KIMS tumble as SC questions drug mark-ups** — Hospital stocks came under pressure after the Supreme Court raised concerns over steep mark-ups on medicines sold through corporate hospitals. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/hospital-stocks-fall-up-to-6-apollo-fortis-kims-tumble-as-sc-questions-drug-mark-ups/articleshow/134589671.cms)
- 2026-09-30 — CNBC-TV18: **Explained - Why Hospital stocks Apollo, Max, Fortis, KIMS are down up to 6% on Wednesday** — A Public Interest Litigation was being heard by the Supreme Court on price fixation of drugs, mandates for generics. The government was also questioned by the Apex Court as to why there is no 16% mark up across all drugs and devices. — [Source](https://www.cnbctv18.com/market/why-hospital-stocks-apollo-max-fortis-global-share-price-are-falling-explained-drug-pricing-markup-supreme-court-observation-20001775.htm)
- 2026-09-29 — Economic Times: **Medanta operator Global Health buys Ghaziabad land for Rs 166 cr to build 350-bed hospital** — Global Health Limited has acquired a land parcel in Ghaziabad for approximately Rs 165.82 crore. This project will consist of a 350-plus bed hospital aimed at increasing healthcare services. The hospital will serve Ghaziabad and nearby regions, including eastern Delhi and Meerut. Global Health operates hospitals across various cities in India and aims to expand its network. This development will enhance the company's presence in the Delhi-NCR healthcare ecosystem. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/medanta-operator-global-health-buys-ghaziabad-land-for-rs-166-cr-to-build-350-bed-hospital/articleshow/134564180.cms)
- 2026-09-29 — BUSINESS: **Global Health acquires 10,560 sq. metre land parcel in Ghaziabad** — For development of proposed 350-bedded hospital — [Source](https://www.business-standard.com/markets/capital-market-news/global-health-acquires-10-560-sq-metre-land-parcel-in-ghaziabad-126092900653_1.html)
- 2026-09-10 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —10 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — One 97 Communications, Global Health, Adani Power, JSW Infrastructure, and Aditya Birla Sun Life Amc. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-10-september-2026-11789001772273.html)
- 2026-09-07 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —7 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today — TCPL Packaging, Innova Captab, Greenply Industries, Global Health, and Apl Apollo Tubes. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-7-september-2026-11788742187187.html)
- 2026-09-01 — Mint: **Stocks to buy for short term: Sagility, Polycab India among 6 stocks experts recommend buying today; do you own any?** — Stocks to buy for the short term: Experts highlight six stocks to buy for short-term gains, backed by robust technical indicators and market momentum. Dive into the analysis to learn more. — [Source](https://www.livemint.com/market/stock-market-news/stocks-to-buy-for-short-term-sagility-polycab-india-among-6-stocks-experts-recommend-buying-today-do-you-own-any-11788234015790.html)
- 2026-08-28 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —28 August 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —Wonderla Holidays, Orkla India, Bharat Heavy Electricals, Adani Power, and Global Health. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-28-august-2026-11787878851830.html)
- 2026-08-26 — MONEYCONTROL: **Buy Global Health; target of Rs 1750: Prabhudas Lilladher** — Prabhudas Lilladher, Global Health, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-global-health-target-of-rs-1750-prabhudas-lilladher-14015922.html)
- 2026-08-03 — CNBC-TV18: **Sensex Today | Stock Market Live Updates: Nifty may open above 24,500; Auto stocks in focus** — Sensex Today | Stock Market Live Updates: The bulls, having ended the week with gains will now be eyeing two levels on the upside, 24,467, which is the recent swing high, and 24,500, which has been a psychological barrier, before the positional swing high of 24,601 could be retested. The Nifty Bank though, continues to struggle with 57,500 continuing to act as a hurdle. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-today-oil-fcnr-rupee-itc-maruti-autos-ioc-divis-zee-stl-banks-share-price-liveblog-19959976.htm)
- 2026-07-31 — CNBC-TV18: **Q1 Results LIVE Updates: Hyundai Motor India shares rise over up 9%; ITC, Maruti report today** — Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-sun-pharma-itc-maruti-suzuki-bajaj-finserv-tata-steel-swiggy-share-price-liveblog-19958383.htm)
- 2026-07-24 — Mint: **Raja Venkatraman recommends three stocks for 24 July** — Market expert Raja Venkatraman shares his top stock picks for 24 July. Here’s his technical outlook and trade strategy. — [Source](https://www.livemint.com/market/stock-market-news/raja-venkatraman-recommends-three-stocks-for-24-july-sensex-nifty-11784818333324.html)
- 2026-07-23 — Economic Times: **India has undertaken transformative reforms to strengthen its healthcare system: J P Nadda** — India hosted the 16th BRICS Health Ministers' Meeting in Chandigarh. The meeting established a network for mental wellness research and collaboration. BRICS nations adopted a declaration to deepen health cooperation and strengthen systems. Initiatives were launched to combat diseases driven by social determinants. Digital health and healthy lifestyle promotion were also key discussion points. — [Source](https://economictimes.indiatimes.com/news/india/india-has-undertaken-transformative-reforms-to-strengthen-its-healthcare-system-j-p-nadda/articleshow/132582549.cms)
- 2026-07-15 — Times of India: **Over 700 dead in Ebola outbreak in DR Congo: First-ever human trial of Bundibugyo Ebola vaccine — when will it be ready?** — Wellness News: More than 700 people have died in the latest Ebola outbreak tearing through the Democratic Republic of the Congo — the worst the country has ever seen. — [Source](https://timesofindia.indiatimes.com/etimes/wellness/over-700-dead-in-ebola-outbreak-in-dr-congo-first-ever-human-trial-of-bundibugyo-ebola-vaccine-when-will-it-be-ready/articleshow/132403515.cms)

## Business profile

**Strategic vision:** Multi-specialty tertiary care provider delivering advanced healthcare services.

### Business segments
- **Hospital Operations:** Medanta operates hospitals providing advanced medical treatments across a broad range of specialties. They focus on integrated, multispecialty care delivered by experienced superspecialist doctors.
- **Ancillary Healthcare Services:** The company offers complementary services including medicine delivery, lab tests, diagnostics, homecare, virtual consultations, and air ambulance services to provide comprehensive patient care.

### Competitive strengths
- Integrated multispecialty care delivery model
- Network of advanced tertiary care hospitals
- Team of experienced superspecialist doctors
- Comprehensive suite of medical and ancillary services

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Acutaas Chemicals Limited (Healthcare)](https://faxioms.com/stocks/acutaas) — +0.30%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Anthem Biosciences Limited (Healthcare)](https://faxioms.com/stocks/anthem) — +0.16%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/medanta
Markdown representation: https://faxioms.com/stocks/medanta?render=md